201 related articles for article (PubMed ID: 29472171)
1. Treatment of uveitis and ankylosing spondylitis refractory to three tumor necrosis factor alpha inhibitors drugs with golimumab.
Chaparro Sanabria JA; Bautista Molano W; Valle Oñate R
Reumatol Clin (Engl Ed); 2020; 16(1):64-65. PubMed ID: 29472171
[No Abstract] [Full Text] [Related]
2. The Effect of Tumor Necrosis Factor-Alpha Inhibitors on Uveitis in Patients with Ankylosing Spondylitis.
Lee S; Park YJ; Lee JY
J Korean Med Sci; 2019 Nov; 34(42):e278. PubMed ID: 31674159
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of tumor necrosis factor alpha and ankylosing spondylitis.
Asli B; Wechsler B; Lemaître C
N Engl J Med; 2003 Jan; 348(4):359-61; author reply 359-61. PubMed ID: 12540654
[No Abstract] [Full Text] [Related]
4. TNF-alpha inhibitors for ankylosing spondylitis.
Maxwell LJ; Zochling J; Boonen A; Singh JA; Veras MM; Tanjong Ghogomu E; Benkhalti Jandu M; Tugwell P; Wells GA
Cochrane Database Syst Rev; 2015 Apr; (4):CD005468. PubMed ID: 25887212
[TBL] [Abstract][Full Text] [Related]
5. Adalimumab (Humira™): a promising monoclonal anti-tumor necrosis factor alpha in ophthalmology.
Neri P; Zucchi M; Allegri P; Lettieri M; Mariotti C; Giovannini A
Int Ophthalmol; 2011 Apr; 31(2):165-73. PubMed ID: 21287227
[TBL] [Abstract][Full Text] [Related]
6. Comparing the risk of developing uveitis in patients initiating anti-tumor necrosis factor therapy for ankylosing spondylitis: an analysis of a large US claims database.
Wendling D; Joshi A; Reilly P; Jalundhwala YJ; Mittal M; Bao Y
Curr Med Res Opin; 2014 Dec; 30(12):2515-21. PubMed ID: 25252590
[TBL] [Abstract][Full Text] [Related]
7. A new strategy of drug treatment in NSAID--unresponsive ankylosing spondylitis.
Chogle AR; Mishra H; Chakravarty A
J Assoc Physicians India; 2007 May; 55():380; author reply 380-1. PubMed ID: 17844703
[No Abstract] [Full Text] [Related]
8. Do Anti-TNF Agents Increase the Risk of Inflammatory Bowel Disease Evolution in Patients with Ankylosing Spondylitis? Real Life Data.
Üsküdar Cansu D; Üsküdar Teke H; Temel T; Ertürk A; Kahraman O; Korkmaz C
J Natl Med Assoc; 2019 Jun; 111(3):262-269. PubMed ID: 30389147
[TBL] [Abstract][Full Text] [Related]
9. Use of Anti-Tumour Necrosis Factor-Alpha Agents in the Management of HLA-B-27-Associated Uveitis: The First Case Series from India.
Lakra R; Shah A; Kaushik V; Biswas J; Dutta Majumder P
Ocul Immunol Inflamm; 2021 Feb; 29(2):232-236. PubMed ID: 32058826
[No Abstract] [Full Text] [Related]
10. Adalimumab for the treatment of ankylosing spondylitis.
Sieper J; Rudwaleit M; Braun J
Expert Opin Pharmacother; 2007 Apr; 8(6):831-8. PubMed ID: 17425478
[TBL] [Abstract][Full Text] [Related]
11. Reasons for Discontinuation and Adverse Effects of TNFα Inhibitors in a Cohort of Patients With Rheumatoid Arthritis and Ankylosing Spondylitis.
García-Lagunar MH; Gutiérrez-Cívicos MR; García-Simón MS; Conesa-Zamora P; Jimenez-Santos E; Cano-Vivar P; García-Márquez A; Muñoz-García I; Viney AC
Ann Pharmacother; 2017 May; 51(5):388-393. PubMed ID: 27920336
[TBL] [Abstract][Full Text] [Related]
12. The effect of comedication with conventional synthetic disease modifying antirheumatic drugs on TNF inhibitor drug survival in patients with ankylosing spondylitis and undifferentiated spondyloarthritis: results from a nationwide prospective study.
Lie E; Kristensen LE; Forsblad-d'Elia H; Zverkova-Sandström T; Askling J; Jacobsson LT;
Ann Rheum Dis; 2015 Jun; 74(6):970-8. PubMed ID: 25710471
[TBL] [Abstract][Full Text] [Related]
13. Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents.
Gao X; Wendling D; Botteman MF; Carter JA; Rao S; Cifaldi M
J Med Econ; 2012; 15(6):1054-63. PubMed ID: 22563743
[TBL] [Abstract][Full Text] [Related]
14. Behçet disease-associated uveitis successfully treated with golimumab.
Mesquida M; Victoria Hernández M; Llorenç V; Pelegrín L; Espinosa G; Dick AD; Adán A
Ocul Immunol Inflamm; 2013 Apr; 21(2):160-2. PubMed ID: 23252659
[TBL] [Abstract][Full Text] [Related]
15. Anti-tumor necrosis factor-α therapy in uveitis.
Cordero-Coma M; Sobrin L
Surv Ophthalmol; 2015; 60(6):575-89. PubMed ID: 26164735
[TBL] [Abstract][Full Text] [Related]
16. Sensorineural hearing loss in ankylosing spondylitis treated with TNF blockers.
Savastano M; Marioni G; Giacomelli L; Ramonda R; Ferraro SM; Punzi L
B-ENT; 2010; 6(3):183-8. PubMed ID: 21090160
[TBL] [Abstract][Full Text] [Related]
17. Comparison of continuation rates with three TNFα antagonists (adalimumab, infliximab, etanercept) in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: Retrospective 10-year study.
Batteux B; Devauchelle A; Boyard PL; Sejourné A; Fardellone P; Goëb V
Joint Bone Spine; 2016 Oct; 83(5):607-9. PubMed ID: 26919803
[No Abstract] [Full Text] [Related]
18. Golimumab (simponi) for inflammatory arthritis.
Med Lett Drugs Ther; 2009 Jul; 51(1316):55-6. PubMed ID: 19590489
[No Abstract] [Full Text] [Related]
19. Anti-TNFα Treatment for HLA-B27-Positive Ankylosing Spondylitis-Related Uveitis.
Kim M; Won JY; Choi SY; Ju JH; Park YH
Am J Ophthalmol; 2016 Oct; 170():32-40. PubMed ID: 27470062
[TBL] [Abstract][Full Text] [Related]
20. Golimumab may induce exacerbation of inflammatory bowel disease when it is used for the treatment of ankylosing spondylitis: a case report with a review of literature.
Bawany MZ; Rafiq E; Thotakura R; Lay R; Silverman AL; Nawras A
Am J Ther; 2014; 21(1):e26-7. PubMed ID: 23344099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
